Wellness and D2C founders, check your labels. The Food Safety and Standards Authority of India (FSSAI) has issued an advisory reinforcing mandatory labelling standards and warning statements for products containing plant and botanical ingredients or their extracts, reported on October 19, 2026.
The regulator found that several food business operators making nutraceuticals, health supplements, food for special dietary use and food for special medical purpose are not adhering to the mandatory labelling requirements under Schedule IV of the 2016 regulations. FSSAI now requires that warning statements be prominent, legible and clear, that manufacturers declare the plant part used, and that no medicinal or disease-cure claims appear on packs. A consolidated list of plant and botanical ingredients carrying mandatory cautionary statements was prepared in consultation with the Ministry of Ayush.
The stakes are regulatory, not advisory: non-compliance violates section 23 of the FSS Act, 2006 and can trigger action under section 52 — including suspension or cancellation of licences and penalties.
For India's booming nutraceutical and D2C wellness startups, this is a compliance sprint: review every SKU's label and formulation against Schedule IV, pull any disease-cure language from packaging and marketing, and document the plant-part declarations.
Why it matters for founders
Regulatory action is a product risk in the wellness category — a licence suspension can freeze sales overnight. Treat this advisory as a checklist: audit labels now, because enforcement follows advisories. Investors in this space will ask about compliance readiness in the next diligence round.